Data / Form D filings / Spotlight Therapeutics, Inc.
Spotlight Therapeutics, Inc.: Form D filings
Spotlight Therapeutics, Inc., a biotechnology company in Hayward, CA, filed 4 Form D notices with the SEC between 2018 and 2022. The latest, on January 5, 2022, reports $32.2 million sold of a $65 million offering to 11 investors.
Find out what Spotlight Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3953 Point Eden Way, Hayward, CA, 94545
- Phone
- (510) 405-5209
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2017
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1726495
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 5, 2022 | New notice | $64,999,973 | $32,204,975 | $32,794,998 | 11 | Dec 10, 2021 | sec.gov |
| Mar 4, 2021 | New notice | $16,000,001 | $15,189,998 | $810,003 | 15 | Sep 10, 2020 | sec.gov |
| Sep 25, 2019 | New notice | $7,133,331 | $6,899,997 | $233,334 | 6 | Sep 9, 2019 | sec.gov |
| Jan 3, 2018 | New notice | $12,000,000 | $7,266,667 | $4,733,333 | 5 | Dec 22, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Mary Haak-Frendscho | Executive Officer | |
| Jacob Corn | Director | |
| Alexander David Marson | Director | |
| Krishna David Yeshwant | Director | |
| Patrick David Hsu | Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
- Tempest Therapeutics, Inc. $7.5 million · Oct 14, 2026
- Lionheart Health, Inc. $387,500 · Oct 7, 2026
- Rakuten Medical, Inc. $9 million · Oct 6, 2026
- Zonaliz, Inc. $2.5 million · Oct 5, 2026
- Altay Therapeutics, Inc. $15.7 million · Oct 2, 2026
- Sialia Therapeutics, Inc. $1.5 million · Sep 29, 2026
- Vetmab Biosciences, Inc. $11.4 million · Sep 29, 2026
Every Form D from the week of Jan 3, 2022 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Spotlight Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.